These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
72 related articles for article (PubMed ID: 8704620)
1. [The effect of haloperidol at a low dose on the development of experimental parkinsonian syndrome]. Korshunov AM; Voronina TA; Churiukanov VV; Iakhno NN Eksp Klin Farmakol; 1995; 58(6):7-9. PubMed ID: 8704620 [TBL] [Abstract][Full Text] [Related]
2. [Evaluation of the capability of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and pyridine derivatives to evoke parkinsonism]. Lermontiva NN; Soliakov LS; Bachurin SO; Tkachenko SE; Serkova TP Biull Eksp Biol Med; 1989 Jun; 107(6):699-701. PubMed ID: 2790166 [TBL] [Abstract][Full Text] [Related]
3. Further validation of LABORAS using various dopaminergic manipulations in mice including MPTP-induced nigro-striatal degeneration. Quinn LP; Stean TO; Chapman H; Brown M; Vidgeon-Hart M; Upton N; Billinton A; Virley DJ J Neurosci Methods; 2006 Sep; 156(1-2):218-27. PubMed ID: 16626808 [TBL] [Abstract][Full Text] [Related]
4. [Multiple microinjections of haloperidol in rat globus pallidus induce vegetative components of parkinsonian syndrome]. Iakimovskiĭ AF Biull Eksp Biol Med; 1998 Jun; 125(6):615-7. PubMed ID: 9693747 [No Abstract] [Full Text] [Related]
5. Antiparkinsonian activity of (+)-PHNO in the MPTP-treated common marmoset. Nomoto M; Stahl S; Jenner P; Marsden CD Mov Disord; 1987; 2(1):37-45. PubMed ID: 2904119 [TBL] [Abstract][Full Text] [Related]
6. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains. Haobam R; Sindhu KM; Chandra G; Mohanakumar KP Behav Brain Res; 2005 Sep; 163(2):159-67. PubMed ID: 15941598 [TBL] [Abstract][Full Text] [Related]
7. [Decrease in motor activity in C57Bl/6 mice as affected by lymphocytes taken from animals with Parkinsonian syndrome induced by 1,2,3,6-tetrahydropyridine (MPTP)]. Kryzhanovskiĭ GN; Davydova TV; Fomina VG; Pletsityĭ KD; Evseev VA; Krupina NA; Kucherianu VG Biull Eksp Biol Med; 1994 Mar; 117(3):232-4. PubMed ID: 8204836 [No Abstract] [Full Text] [Related]
8. [Effects of substance P on experimental parkinsonian syndrome]. Kryzhanovskiĭ GN; Atadzhanov MA; Kucherianu VG Biull Eksp Biol Med; 1989 Oct; 108(10):404-7. PubMed ID: 2480824 [TBL] [Abstract][Full Text] [Related]
9. [Clinical and biochemical parameters of parkinsonism induced by 1-methyl-4-phenyl-1,2,2,6-tetrahydropyridine and its methyl-phenyl and methoxy-phenyl derivatives in C57Bl/6 mice]. Lermontova NN; Soliakov LS; Bachurin SO; Serkova TP; Petrova LN; Dranyĭ OA; Tkachenko SE; Kalashnikov VV Biull Eksp Biol Med; 1990 Oct; 110(10):397-9. PubMed ID: 2279092 [TBL] [Abstract][Full Text] [Related]
10. Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors. Steece-Collier K; Chambers LK; Jaw-Tsai SS; Menniti FS; Greenamyre JT Exp Neurol; 2000 May; 163(1):239-43. PubMed ID: 10785463 [TBL] [Abstract][Full Text] [Related]
11. Effects of blocking the dopamine biosynthesis and of neurotoxic dopamine depletion with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on voluntary wheel running in mice. Leng A; Mura A; Hengerer B; Feldon J; Ferger B Behav Brain Res; 2004 Oct; 154(2):375-83. PubMed ID: 15313025 [TBL] [Abstract][Full Text] [Related]
12. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638 [TBL] [Abstract][Full Text] [Related]
14. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors. Morissette M; Dridi M; Calon F; Hadj Tahar A; Meltzer LT; Bédard PJ; Di Paolo T Synapse; 2006 Sep; 60(3):239-50. PubMed ID: 16739115 [TBL] [Abstract][Full Text] [Related]
15. l-dopa-induced reversal in striatal glutamate following partial depletion of nigrostriatal dopamine with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Holmer HK; Keyghobadi M; Moore C; Meshul CK Neuroscience; 2005; 136(1):333-41. PubMed ID: 16198485 [TBL] [Abstract][Full Text] [Related]
16. Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism. Sagi Y; Mandel S; Amit T; Youdim MB Neurobiol Dis; 2007 Jan; 25(1):35-44. PubMed ID: 17055733 [TBL] [Abstract][Full Text] [Related]
17. [The effect of prolonged parenteral administration of liposomes and L-Dopa incorporated into liposomes on metabolism of dopamine and its metabolites in the striatum of mice with experimental parkinsonian syndrome]. Iurasov VV; Kucherianu VG; Kudrin VS; Zhigal'tsev IV; Nikushkin EV; Sandalov IuG; Kaplun AP; Shvets VI Biull Eksp Biol Med; 1997 Feb; 123(2):150-3. PubMed ID: 9280483 [No Abstract] [Full Text] [Related]
18. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus). Pearce RK; Jackson M; Smith L; Jenner P; Marsden CD Mov Disord; 1995 Nov; 10(6):731-40. PubMed ID: 8749992 [TBL] [Abstract][Full Text] [Related]
19. [The effect of liposomal form of L-Dopa on the development of parkinsonian syndrome in mice]. Kucherianu VG; Iurasov VV; Kryzhanovskiĭ GN; Nikushkin EV; Zhigal'tsev IV; Kaplun VP; Shvets VI Biull Eksp Biol Med; 1997 Jan; 123(1):29-33. PubMed ID: 9213451 [No Abstract] [Full Text] [Related]
20. [Influence of hemantane and doxycycline on MPTP-evoked behavior violations in C57BL/6 mice]. Kovalev GI; Salimov RM Eksp Klin Farmakol; 2011; 74(5):3-5. PubMed ID: 21809690 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]